New EU project aims to learn more about hormone-disrupting chemicals

Hormone-disrupting chemicals in our environment can affect early neurodevelopment in children, but little is known about the exact mechanisms for this interference. A new EU funded research project, coordinated from Karolinska Institutet, now aims to learn more and to develop better screening and testing tools.

The project called ENDpoiNTs (Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity) includes 16 partners in Europe, United States and Australia. Coordinator for the entire project is Dr Joëlle Rüegg, a molecular biologist and associate professor at the Institute of Environmental Medicine (IMM), Karolinska Institutet and also affiliated to the research organization Swetox. The project is funded through the Horizon2020 framework program with EUR 6.89 million or about SEK 70 million.

The ENDpoiNTs researchers hope to clarify the causal link between hormone-disrupting chemicals and neurodevelopmental injuries by integrating expertise from different, but today largely independent, toxicology communities, and by combining novel experimental technologies with advanced biostatistics on human epidemiological and biomonitoring data. Another important aim is to ensure that the tools developed by the project can successfully be used in society.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Postmenopausal hormone therapy use declines amidst risk-benefit concerns